ERBB2 and cancer: Furthermore, stage IIB cancer was the most common, constituting 192 (33.9%) of the patients, with frequent molecular subtypes being positive ER (427 (75.5%)), followed by positive PR (396 (70.1%)), and then negative HER2 (385 (68.1%)).